Natixis Kymera Therapeutics, Inc. Transaction History

Natixis

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$22.9 - $43.57 $45,616 - $86,791	-1,992 Reduced 50.16%	1,979 $79,000
Q4 2023 Feb 13, 2024	SELL	$10.97 - $26.84 $2,292 - $5,609	-209 Reduced 5.0%	3,971 $101,000
Q3 2023 Nov 14, 2023	BUY	$13.9 - $23.88 $58,102 - $99,818	4,180 New	4,180 $58,000
Q2 2022 Aug 12, 2022	SELL	$14.13 - $42.55 $124,386 - $374,567	-8,803 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$35.3 - $64.68 $294,578 - $539,754	-8,345 Reduced 48.66%	8,803 $373,000
Q4 2021 Feb 14, 2022	SELL	$49.91 - $65.56 $1.95 Million - $2.56 Million	-38,991 Reduced 69.45%	17,148 $1.09 Million
Q3 2021 Nov 12, 2021	BUY	$47.8 - $66.66 $2.37 Million - $3.3 Million	49,575 Added 755.26%	56,139 $3.3 Million
Q2 2021 Aug 13, 2021	BUY	$31.08 - $51.95 $204,009 - $340,999	6,564 New	6,564 $318,000

184

64.4M

50.6K

81.7K

Ticker KYMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,705,800
Market Cap $2.28B
Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.